Additional file 1 of Clinical features and treatment outcomes of pediatric Langerhans cell histiocytosis with macrophage activation syndrome-hemophagocytic lymphohistiocytosis
- Resource Type
- Authors
- Wang, Dong; Chen, Xi-Hua; Wei, Ang; Zhou, Chun-Ju; Zhang, Xue; Ma, Hong-Hao; Lian, Hong-Yun; Zhang, Li; Zhang, Qing; Huang, Xiao-Tong; Wang, Chan-Juan; Yang, Ying; Liu, Wei; Wang, Tian-You; Li, Zhi-Gang; Cui, Lei; Zhang, Rui
- Source
- Subject
- fungi
hormones, hormone substitutes, and hormone antagonists
- Language
Additional file 1: Table S1. Clinical characteristics and biologic parameters of LCH patients with MAS-HLH. Table S2. Longitudinal evaluation of cell-free BRAF-V600E during dabrafenib treatment. Figure S1. Histology of LCH lesions obtained from a skin biopsy (A-C) or a bone marrow biopsy (D-F) in the LCH patients with MAS-HLH. (A) and (D): HE staining; (B) and (E): CD1a-positive immunostaining; (C) and (F): CD207 (langerin)-positive immunostaining. Figure S2. Study cohorts of pediatric LCH and MAS-HLH. Figure S3. Comparison of DAS after one month of dabrafenib and five weeks (two therapeutic courses) of second-line chemotherapy.